Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323191 · ClinicalTrials.gov registry record · Phase 1
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
A Phase 1 study of Solid Cancers, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 221
- Enrollment target
- 12
- Study locations
NCT02323191: Completed Phase 1 study of Solid Cancers, sponsored by Hoffmann-La Roche.
NCT02323191 is a Phase 1 study of Solid Cancers that has completed, run by Hoffmann-La Roche. The registered enrollment target is 221 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (268% higher). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02323191, a Phase 1 study of Solid Cancers, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 221 participants
- Enrollment target
- 12
- Study locations
Study Summary
This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participants who receive emactuzumab and atezolizumab will continue to receive study drug as long as they experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data, biopsy results (if available), and clinical status, or withdrawal of consent.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Emactuzumab
Study Locations (12)
Other
- Cliniques Universitaires St-Luc - Brussels
- Centre Leon Berard; Departement Oncologie Medicale - Lyon
- Institut Claudius Regaud; Departement Oncologie Medicale - Toulouse
- Institut Gustave Roussy; Departement Oncologie Medicale - Villejuif
- Hospital del Mar; Servicio de Oncologia - Barcelona
- Centro Integral Oncológico Clara Campal Ensayos Clínicos START - Madrid
Massachusetts
- Massachusetts General Hospital. - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber - Harvard - Boston
Connecticut
- Yale Cancer Center; Medical Oncology - New Haven
New York
- Memorial Sloan-Kettering Cancer Center Breast & Imaging Center - New York
Navarre
- Clinica Universitaria de Navarra; Servicio de Oncologia - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2015-01-19 |
| Est. Completion | 2020-08-21 |
| Phase | Phase 1 |
What the finished NCT02323191 record still lists
NCT02323191 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (268% higher).
The record links to 1 condition, with Solid Cancers appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02323191 lists 12 locations in 5 states (Other, Massachusetts, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02323191 about?
NCT02323191 is a clinical study titled "A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors". This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participant...
What is the current status of trial NCT02323191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 221 participants. The study started on 2015-01-19. Estimated completion is 2020-08-21.
What conditions does trial NCT02323191 study?
This clinical trial studies the following conditions: Solid Cancers.
What interventions are being tested in trial NCT02323191?
The interventions under investigation include: Atezolizumab (DRUG), Emactuzumab (DRUG).
Who is sponsoring clinical trial NCT02323191?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02323191 being conducted?
This trial has 12 study locations across Connecticut, Massachusetts, New York, Navarre. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02323191's enrollment target sits among peer trials
221 230th of 2000 higher than 1,771 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI